As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. 

The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings.

Recent guidance from the American Diabetes Association’s Standards of Care in Overweight and Obesity also stresses a person-centered approach, including access, tolerability, side effects, and patient preferences.

The Logistics of the Switch

When a switch is needed, the aim is to keep the transition smooth without moving too fast. Because many of these agents have extended half-lives, a medication-free interval is generally unnecessary. In most cases, the new medication can begin when the next dose of the prior agent would have been due. That helps avoid a treatment gap while reducing the risk for overlap. Practical switching guidance published in Clinical Diabetes supports this kind of step-by-step planning for GLP-1 receptor agonists.

“Because these are all once-weekly or daily agents with long half-lives, there is no washout period needed for a class switch — start the new drug when the next dose of the old one would have been due,” said Hani Soudah, MD, PhD, associate professor of medicine at WashU Medicine in St. Louis, who is a weight management and obesity specialist.

Timing matters, too. Overlapping therapies or continuing low-value add-ons such as DPP-4 inhibitors may increase side effects and costs without added benefit. The goal is to keep treatment moving without duplicating therapy.

Individualizing Titration Strategies

A common pitfall is treating every switch the same way. Although it can be tempting to move patients quickly toward the highest approved dose, titration should reflect prior exposure, clinical response, and tolerability. Soudah said patients who “sailed through the first titration usually tolerate a faster reescalation,” while those who struggled initially often need a slower approach. A 2024 practical guide in the World Journal of Diabetes also notes that choosing, titrating, and switching among GLP-1 and dual GIP/GLP-1 receptor agonists can be complicated in everyday practice.

“Obesity medications should rather be initiated at a low dose and up-titrated gradually as needed based on tolerability and clinical response,” added Marci Laudenslager, MD, MHS, DABOM, assistant professor of medicine at Johns Hopkins University School of Medicine, and an obesity medicine physician at the Johns Hopkins Healthful Eating, Activity & Weight Program both in Baltimore.

Common Errors in Clinical Transitions

Dose matching is often where switches get tricky because GLP-1 drugs do not line up neatly. Treating doses as interchangeable can worsen gastrointestinal side effects, and after a treatment gap, patients may need to restart lower and build back up. Expert consensus in the International Journal of Clinical Practice recommends individualizing switches based on prior dose, duration, tolerance, and patient-specific factors.

“If a patient has not been taking the GLP-1 for more than 2-3 weeks, you need to retitrate up, because starting an equivalent dose can cause GI [gastrointestinal] intolerance,” said Susan Spratt, MD, professor of medicine and professor in family medicine and community health at Duke University School of Medicine in Durham, North Carolina.

Preemptive counseling is essential during medication transitions. Patients should know that nausea, constipation, or appetite changes may recur temporarily after switching, even if the prior agent was well tolerated. Clear guidance can prevent patients from mistaking expected side effects for treatment failure and stopping therapy early, experts said.

Managing Diabetes and Glycemic Risk

For patients with type 2 diabetes, switching requires extra attention. A stronger or differently dosed agent can lower glucose quickly, especially when insulin or a sulfonylurea is also in the regimen. Hypoglycemia should be anticipated before it becomes a problem.

“Have patients check glucose more frequently — daily or more — for at least the first 4 weeks after the switch and after each dose increase,” said Soudah.

Primary care providers should also have a plan for reducing or temporarily holding insulin or sulfonylurea doses as the new GLP-1 agent starts working. Continuous glucose monitoring can be especially helpful because it shows day-to-day glucose patterns that A1c cannot capture, according to the American Diabetes Association. “The A1c does not tell the whole story,” Spratt said, noting that patients may have unrecognized hypoglycemia or near-hypoglycemia, particularly overnight. Together, these steps can support safer, more responsive dose escalation.

Patient Counseling and Symptom Management

Laudenslager emphasized that follow-up matters during this period. “Appropriate counseling and close follow-up are essential when transitioning pharmacotherapy for any chronic illness, and the same holds true for obesity pharmacotherapy,” she said. “Patients should be seen within a month for evaluation of safety, tolerability, and efficacy.”

“It is best to set a goal of weight stability, rather than weight loss, during a transition in therapy,” continued Laudenslager.

High-Risk Switches

Some transitions call for extra caution. Older patients who may need closer attention include those with a history of pancreatitis, gallbladder disease, complex medication regimens, or age-related frailty. Switching should not be automatic. It is an opportunity to reassess the full treatment plan and confirm that the medication still fits the patient’s broader health needs. In older adults, that may also mean monitoring more closely for dehydration, reduced intake, and loss of muscle or bone mass.

For primary care clinicians, GLP-1 transitions should be deliberate, individualized, and closely monitored. Soudah said the decision comes down to “why the switch is happening, how much incretin exposure the patient already has, and how they tolerated the prior agent.” By keeping those factors front and center, these can help clinicians choose a safer starting dose, anticipate side effects, and keep patients on effective treatment.

The authors reported having no relevant financial disclosures.